EGFR and neoplasm: In contrast, TKIs inhibit kinase activity and autophosphorylation by competitively binding the ATP binding site of the EGFR tyrosine kinase domain and blocking EGFR-mediated signal transduction, thus inhibiting tumor cell proliferation (Pao and Chmielecki, 2010; Roskoski, 2014).